David S. Hong

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Papers

Driven by 84 papers — median percentile 0. Top paper: “Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial”.

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

Nature Medicine(2023)10.1038/s41591-022-02128-z

N/A

5.6DataRank · unranked

197 citations

Brian A. Van Tine, Swethajit Biswas, Cheryl McAlpine, Melissa L. Johnson, Anthony J. Olszanski +39 more

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature Medicine(2023)10.1038/s41591-022-02103-8

N/A

4.3DataRank · unranked

388 citations

Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam +44 more

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000347

N/A

4.0DataRank · unranked

131 citations

Funda Meric‐Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar, Jordi Rodon Ahnert +35 more

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

British Journal of Cancer(2020)10.1038/s41416-020-0802-1

N/A

3.4DataRank · unranked

924 citations

Yoon‐Koo Kang, Mitesh J. Borad, Jasgit C. Sachdev, Samuel Ejadi, Ho Yeong Lim +18 more

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

Nature Medicine(2023)10.1038/s41591-023-02452-y

N/A

2.2DataRank · unranked

106 citations

Marcus O. Butler, Roisin E. O’Cearbhaill, David Y. Oh, Melissa L. Johnson, Kevin Zikaras +10 more

Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0328

N/A

2.1DataRank · unranked

61 citations

Omid Hamid, Asha Nayak-Kapoor, Solmaz Sahebjam, Mario Sznol, Agron Collaku +4 more

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

Nature Medicine(2024)10.1038/s41591-023-02717-6

N/A

2.0DataRank · unranked

94 citations

Marwan Fakih, John H. Strickler, Rona Yaeger, Toshiki Masuishi, Edward Kim +14 more

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

The Oncologist(2022)10.1093/oncolo/oyac080

N/A

1.7DataRank · unranked

49 citations

Christina S. Baik, Jessica R. Bauman, Jill Gilbert, Marcia S. Brose, Juneko E. Grilley‐Olson +13 more

Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-004822

N/A

1.4DataRank · unranked

44 citations

Bettzy Stephen, Daniel D. Karp, Sarina A. Piha‐Paul, David S. Hong, D Jain +10 more

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1215

N/A

1.3DataRank · unranked

41 citations

Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah +17 more

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Cancer Research Communications(2023)10.1158/2767-9764.crc-22-0260

N/A

0.943DataRank · unranked

37 citations

Niamh Coleman, Sarina A. Piha‐Paul, Apostolia M. Tsimberidou, Filip Jankú, Jordi Rodón +13 more

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas

Cancer(2023)10.1002/cncr.35036

N/A

0.937DataRank · unranked

25 citations

Lin Shen, David S. Hong, Ray McDermott, Vicki L. Keedy, Michela Casanova +19 more

Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors

Frontiers in Oncology(2022)10.3389/fonc.2022.818679

N/A

0.830DataRank · unranked

20 citations

Marcus O. Butler, Russell K. Pachynski, Ryan J. Sullivan, Partow Kebriaei, Sarah Boross-Harmer +20 more

Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0177

N/A

0.828DataRank · unranked

248 citations

Megan T. Hoffman, Laleh Abbassi, Ziyue Li, Francesca Paradiso, Brendan D. Parent +50 more

Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000537

N/A

0.808DataRank · unranked

217 citations

Rishab Ramapriyan, Ahmed Younes, Mauricio S. Caetano, Hari Menon, Nathan Comeaux +16 more

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1420

N/A

0.787DataRank · unranked

189 citations

Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou +61 more

Mechanisms of Resistance to KRASG12C-Targeted Therapy

Cancer Discovery(2021)10.1158/2159-8290.cd-20-1616

N/A

0.751DataRank · unranked

148 citations

Amadeo B. Biter, David S. Hong, Neal S. Akhave

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3629

N/A

0.719DataRank · unranked

21 citations

Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing +29 more

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3313

N/A

0.659DataRank · unranked

80 citations

Michael A. Postow, Bartosz Chmielowski, Ryan J. Sullivan, Amita Patnaik, Ezra E.W. Cohen +12 more

Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data

Frontiers in Immunology(2022)10.3389/fimmu.2022.1027235

N/A

0.657DataRank · unranked

79 citations

Cheng‐En Hsieh, Heather Lin, Kate J. Krause, Ying Yuan, Amadeo B. Biter +4 more

Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS -Mutant Non–Small Cell Lung Cancer

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0421

N/A

0.633DataRank · unranked

67 citations

Ximo Pechuan-Jorge, Teng Zhou, Minh Truong, Xin Hu, Frank Rojas +22 more

Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2024-010013

N/A

0.617DataRank · unranked

22 citations

Shaun O’Brien, Rahul A. Sheth, David S. Hong, Aung Naing, Xiao–Ping Zhang +7 more

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology

npj Precision Oncology(2022)10.1038/s41698-022-00317-0

N/A

0.607DataRank · unranked

17 citations

Siqing Fu, David S. Hong, Daniel D. Karp, Sarina A. Piha‐Paul, Vivek Subbiah +18 more

A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden

Nature Biomedical Engineering(2021)10.1038/s41551-020-00662-0

N/A

0.587DataRank · unranked

49 citations

Zhihui Wang, Dalia Elganainy, Karine A. Al Feghali, Marija Plodinec, George A. Calin +11 more

A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma

Blood Advances(2023)10.1182/bloodadvances.2023010653

N/A

0.574DataRank · unranked

45 citations

Andrew Jallouk, Qing Deng, Xubin Li, Lei Feng, Ryan Sun +23 more

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

British Journal of Cancer(2021)10.1038/s41416-020-01230-8

N/A

0.568DataRank · unranked

43 citations

Filip Jankú, Vivek Subbiah, John Stewart, Sapna P. Patel, Ahmed O. Kaseb +10 more

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study

npj Precision Oncology(2021)10.1038/s41698-021-00159-2

N/A

0.505DataRank · unranked

28 citations

David S. Hong, Siqing Fu, Daniel D. Karp, Sarina A. Piha‐Paul, Merrill S. Kies +16 more

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

Scientific Reports(2022)10.1038/s41598-022-12669-5

N/A

0.483DataRank · unranked

24 citations

Funda Meric‐Bernstam, David S. Hong, Filip Jankú, Aung Naing, Sarina A. Piha‐Paul +13 more

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer

BMJ Oncology(2024)10.1136/bmjonc-2023-000133

N/A

0.473DataRank · unranked

13 citations

Genevieve Hartley, Coline Couillault, Ying Yuan, Heather Lin, Courtney Nicholas +18 more

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study

npj Precision Oncology(2023)10.1038/s41698-022-00341-0

N/A

0.470DataRank · unranked

22 citations

Jason Roszik, Filip Jankú, David S. Hong, Shumei Kato, Aung Naing +11 more

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

Scientific Reports(2020)10.1038/s41598-020-58366-z

N/A

0.464DataRank · unranked

21 citations

Filip Jankú, Sarina A. Piha‐Paul, Kenneth R. Hess, Russell R. Broaddus, Lidong Liu +11 more

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

ESMO Open(2021)10.1016/j.esmoop.2021.100079

N/A

0.396DataRank · unranked

13 citations

Ruth Sacks, Ishwaria M. Subbiah, Neele Drobnitzky, Sarina A. Piha‐Paul, David S. Hong +15 more

Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2819

N/A

0.385DataRank · unranked

12 citations

Yingao Zhang, Heather Lin, Oriol Mirallas, Pablo Álvarez Ballesteros, Mirella Nardo +19 more

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Scientific Reports(2022)10.1038/s41598-022-16588-3

N/A

0.375DataRank · unranked

4 citations

David S. Hong, Christine B. Peterson, Bettzy Stephen, Ecaterina E. Dumbrava, Shubbam Pant +18 more

Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-20-0751

N/A

0.373DataRank · unranked

11 citations

Andrew W. Hahn, Pavlos Msaouel, Alexander Andreev-Drakhlin, Funda Meric‐Bernstam, Aung Naing +17 more

Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration

JCI Insight(2023)10.1172/jci.insight.169150

N/A

0.373DataRank · unranked

11 citations

Seth T. Gammon, Federica Pisaneschi, Akash R. Boda, Casey R. Ager, David Piwnica‐Worms +3 more

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2509

N/A

0.345DataRank · unranked

9 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3952

N/A

0.330DataRank · unranked

8 citations

Filip Jankú, Siqing Fu, Ecaterina E. Dumbrava, David S. Hong, Daniel D. Karp +20 more

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

npj Precision Oncology(2023)10.1038/s41698-023-00369-w

N/A

0.312DataRank · unranked

7 citations

Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang +16 more

Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009975

N/A

0.271DataRank · unranked

4 citations

Xinyan Xu, Girish S. Shroff, Nathan Comeaux, Wei Li, Jordi Rodon Ahnert +7 more

Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity

Research Square(2022)10.21203/rs.3.rs-1506700/v1

N/A

0.269DataRank · unranked

5 citations

Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka +43 more

Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer

Cancer(2023)10.1002/cncr.34773

N/A

0.269DataRank · unranked

5 citations

Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina A. Piha‐Paul, Julia Ann Moore +18 more

Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2564

N/A

0.241DataRank · unranked

4 citations

Matthew J. Reilley, Amadeo B. Biter, JoAnn Lim, Stacie A. Bean, Ly M. Nguyen +14 more

Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3108

N/A

0.241DataRank · unranked

4 citations

Zihan Wei, David S. Hong, Edith P. Mitchell, James A. Zwiebel, Elad Sharon +15 more

Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling

medRxiv(2021)10.1101/2021.05.10.21256419

N/A

0.235DataRank · unranked

3 citations

Geoffrey V. Martin, Zhihui Wang, Bruna Corradetti, Mauro Ferrari, Nestor F. Esnaola +16 more

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial

Journal of Immunotherapy and Precision Oncology(2025)10.36401/jipo-24-17

N/A

0.217DataRank · unranked

3 citations

Mohamed A. Gouda, Matthew J. Reilley, Amadeo B. Biter, JoAnn Lim, Stacie A. Bean +15 more

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

Cancer Medicine(2025)10.1002/cam4.70280

N/A

0.212DataRank · unranked

3 citations

Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bülent Yılmaz, Bettzy Stephen +16 more

Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial

Journal of Immunotherapy and Precision Oncology(2025)10.36401/jipo-24-27

N/A

0.179DataRank · unranked

2 citations

Camila Bragança Xavier, Bettzy Stephen, Jeffrey How, Justin T. Moyers, Vivek Subbiah +3 more

Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors

JCO Precision Oncology(2023)10.1200/po.23.00217

N/A

0.165DataRank · unranked

2 citations

David S. Hong, Alexander Drilon, Marcia S. Brose

Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.07.004

N/A

0.165DataRank · unranked

2 citations

Andrew W. Hahn, Pavlos Msaouel, Funda Meric‐Bernstam, Nathaniel R. Wilson, Aung Naing +18 more

638P Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center

Annals of Oncology(2024)10.1016/j.annonc.2024.08.705

N/A

0.104DataRank · unranked

1 citations

Siqing Fu, David S. Hong, S.A. Piha-Paul, A. Naing, J. Rodon +15 more

Associations between the gut microbiome and fatigue in cancer patients

Scientific Reports(2021)10.1038/s41598-021-84783-9

N/A

0DataRank · unranked

45 citations

Tito R. Mendoza, Liangliang Zhang, Siqing Fu, Sarina A. Piha‐Paul, David S. Hong +10 more

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

ESMO Open(2021)10.1016/j.esmoop.2021.100230

N/A

0DataRank · unranked

41 citations

S. Greg Call, Helen J. Huang, A.L. Stuckett, Kiran Madwani, Abha Adat +16 more

542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients

Annals of Oncology(2020)10.1016/j.annonc.2020.08.656

N/A

0DataRank · unranked

3 citations

David S. Hong, Andrew Briggs, Jesús García‐Foncillas, Ulrik Lassen, Gilles Vassal +9 more

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

The Oncologist(2024)10.1093/oncolo/oyad338

N/A

0DataRank · unranked

27 citations

Binghe Xu, Ecaterina E. Dumbrava, Siqing Fu, Daniel D. Karp, Funda Meric‐Bernstam +20 more

Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0037

N/A

0DataRank · unranked

30 citations

William D. Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler +23 more

Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer

Journal of Cancer Immunology(2024)10.33696/cancerimmunol.6.086

N/A

0DataRank · unranked

12 citations

David S. Hong, Hirotaka Miyashita

Hybridizing mechanistic modeling and deep learning for personalized survival prediction after immune checkpoint inhibitor immunotherapy

npj Systems Biology and Applications(2024)10.1038/s41540-024-00415-8

N/A

0DataRank · unranked

11 citations

Prashant Dogra, Caroline Chung, Eugene J. Koay, James W. Welsh, David S. Hong +3 more

Obesity and Outcomes in Adoptive Cellular Therapy in Solid Tumors

JAMA Network Open(2024)10.1001/jamanetworkopen.2024.47617

N/A

0DataRank · unranked

1 citations

Mirella Nardo, Cheuk Hong Leung, Heather Lin, Lei Kang, Hung Le +3 more

Hybridizing mechanistic mathematical modeling with deep learning methods to predict individual cancer patient survival after immune checkpoint inhibitor therapy

Research Square(2024)10.21203/rs.3.rs-4151883/v1

N/A

0DataRank · unranked

1 citations

Prashant Dogra, Caroline Chung, Eugene J. Koay, James W. Welsh, David S. Hong +3 more

Best Practice Guidelines for Use of Reference Points in Radiation Oncology Information Systems to Aggregate Longitudinal Dosimetric Data

Practical Radiation Oncology(2024)10.1016/j.prro.2024.09.016

N/A

0DataRank · unranked

0 citations

Y. Jourani, Emily Hirata, T.R. McNutt, Tony Tadic, Kristy K. Brock +10 more

Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy

Science Advances(2020)10.1126/sciadv.aay6298

N/A

0DataRank · unranked

65 citations

Dalia Elganainy, Charles X. Wang, Zhihui Wang, Shu‐Hsia Chen, Nestor F. Esnaola +7 more

Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2310

N/A

0DataRank · unranked

21 citations

Alvaro G. Paula, David Molkentine, Laura D. Hover, Monique B. Nilsson, Natalie I. Vokes +17 more

Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.04.583

N/A

0DataRank · unranked

5 citations

Anne M. Mills, Brooke E. Howitt, Rachel N. Grisham, Elizabeth D. Euscher, Hyun Soo Kim +16 more

Diet in adolescent and young adult patients with cancer and cancer survivors: a scoping review

Supportive Care in Cancer(2025)10.1007/s00520-025-09555-x

N/A

0DataRank · unranked

0 citations

Robert L. Sucholeiki, Joya Chandra, J. Andrew Livingston, Michael Roth, David S. Hong +2 more

532 A phase 1 dose escalation and dose expansion trial of NP-101 in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts(2025)10.1136/jitc-2025-sitc2025.0532

N/A

0DataRank · unranked

0 citations

Bettzy Stephen, Serdar A. Gurses, Michelle York Gocio, Mohamed Omar Kaseb, Yali Yang +18 more

Phase I study of bevacizumab and temsirolimus combination therapy in advanced malignancies: safety, efficacy, and ovarian cancer expansion

The Oncologist(2025)10.1093/oncolo/oyaf413

N/A

0DataRank · unranked

0 citations

Chieh Tseng, Emily Thompson, R. Jason Stafford, Hung Le, Lei Kang +12 more

Uzatresgene autoleucel autologous T-cell monotherapy for advanced solid tumors: SURPASS, a phase 1, open-label trial

10.21203/rs.3.rs-9238113/v1

N/A

0DataRank · unranked

0 citations

Victor Moreno, Kathleen Moore, Adam Asch, Brian A. Van Tine, John Charlson +31 more

Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.004

N/A

0DataRank · unranked

8 citations

Siqing Fu, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Fechukwu Akhmedzhanov, Bülent Yılmaz +16 more

Dietary influences on symptomatic and non-symptomatic toxicities during cancer treatment: A narrative review

Cancer Treatment Reviews(2022)10.1016/j.ctrv.2022.102408

N/A

0DataRank · unranked

15 citations

David S. Hong, Goldy C. George, Alan Kim

Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.03.013

N/A

0DataRank · unranked

20 citations

Goldy C. George, Mirella Nardo, Kate J. Krause, Amir A. Jazaeri, Amadeo B. Biter +2 more

Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5565

N/A

0DataRank · unranked

0 citations

Siqing Fu, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Fechukwu Akhmedzhanov, Bülent Yılmaz +15 more

Operational Ontology for Oncology (O3): A Professional Society-Based, Multistakeholder, Consensus-Driven Informatics Standard Supporting Clinical and Research Use of Real-World Data From Patients Treated for Cancer

International Journal of Radiation Oncology*Biology*Physics(2023)10.1016/j.ijrobp.2023.05.033

N/A

0DataRank · unranked

36 citations

Mary Feng, Kristy K. Brock, Randi Kudner, Peter Balter, Jeffrey C. Buchsbaum +48 more

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

OncoTargets and Therapy(2021)10.2147/ott.s291801

N/A

0DataRank · unranked

3 citations

Ecaterina E. Dumbrava, Binoj C. Nair, Wendy Xiong, Xu Li, Rosa Mostorino +12 more

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3854

N/A

0DataRank · unranked

31 citations

Diana Merino Vega, Lola A. Fashoyin‐Aje, Suparna Wedam, Gwynn Ison, Sol Atienza +9 more

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Cancer(2023)10.1002/cncr.35063

N/A

0DataRank · unranked

17 citations

Jibran Ahmed, Bettzy Stephen, Sarina A. Piha‐Paul, Daniel D. Karp, Abdulrazzak Zarifa +13 more

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer

Journal of Immunotherapy and Precision Oncology(2023)10.36401/jipo-22-23

N/A

0DataRank · unranked

1 citations

Heather Lin, Siqing Fu, Amadeo B. Biter, Ecaterina E. Dumbrava, Daniel D. Karp +15 more

Data from Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

(2023)10.1158/1078-0432.c.6519332.v1

N/A

0DataRank · unranked

0 citations

J. Jack Lee, David S. Hong, Maurie Markman, Jing Gong, Aung Naing +3 more

Data from Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse

(2023)10.1158/1078-0432.c.6519332

N/A

0DataRank · unranked

0 citations

J. Jack Lee, David S. Hong, Maurie Markman, Jing Gong, Aung Naing +3 more

Data from Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

(2023)10.1158/1078-0432.c.6529733

N/A

0DataRank · unranked

0 citations

William D. Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler +23 more

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Data from Phase I Study of P-cadherin–targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors

(2023)10.1158/1078-0432.c.6529733.v1

N/A

0DataRank · unranked

0 citations

William D. Erwin, Osama Mawlawi, Asa McCoy, David Wages, Catherine Wheeler +23 more

Data from Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

(2023)10.1158/1078-0432.c.6532743.v1

Top 100%

0DataRank

Top 100%0 citations

Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu +18 more

Baseline symptom, health status, and health utilities in patients in early-phase clinical trials combining immune checkpoint blockade with other anticancer therapies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12117

N/A

0DataRank · unranked

0 citations

Sarina A. Piha‐Paul, Siqing Fu, Jordi Rodon Ahnert, Timothy A. Yap, Vivek Subbiah +10 more

David S. Hong

Indexed papers

Top data-sharing exemplar

Papers